March 2024: The Food and Drug Administration has granted approval for the use of nivolumab (Opdivo, Bristol-Myers Squibb Company) in conjunction with cisplatin and gemcitabine as the initial treatment for adult patients with unres..
Pebruari 2024: Administrasi Pangan sareng Narkoba parantos nyepetkeun prosés persetujuan pikeun dua ubar, enfortumab vedotin-ejfv (Padcev, Astellas Pharma) sareng pembrolizumab (Keytruda, Merck). Obat ieu dimaksudkeun pikeun ngubaran jalma kalawan lokal..
Agustus 2021: Nivolumab (Opdivo, Bristol-Myers Squibb Co.) parantos disatujuan ku Administrasi Pangan sareng Narkoba pikeun pangobatan adjuvan pasién karsinoma urothelial (UC) anu résiko luhur kanceuh nuturkeun rad ..
Agustus 2021: Enfortumab vedotin-ejfv (Padcev, Astellas Pharma US, Inc.), kombinasi antibodi anu diarahkeun Nectin-4 sareng inhibitor microtubule, parantos disatujuan ku Administrasi Pangan sareng Narkoba pikeun pasien dewasa anu adv..
Agustus 2021: Sacituzumab govitecan (Trodelvy, Immunomedics Inc.) dipasihan persetujuan anu dipercepat ku Administrasi Pangan sareng Narkoba pikeun penderita kanker urothelial anu maju atanapi metastatik lokal (mUC) anu sateuacanna nampi ..